CLINICAL TRIALS PROFILE FOR ISTRADEFYLLINE

All Clinical Trials for ISTRADEFYLLINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00199355 ↗	A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa	Completed	Kyowa Hakko Kirin Company, Limited	Phase 2	2005-04-01	To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
NCT00199355 ↗	A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa	Completed	Kyowa Kirin Co., Ltd.	Phase 2	2005-04-01	To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
NCT00199368 ↗	An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018	Completed	Kyowa Hakko Kirin UK, Ltd.	Phase 3	2004-10-01	This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
NCT00199368 ↗	An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018	Completed	Kyowa Kirin Pharmaceutical Development, Inc.	Phase 3	2004-10-01	This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
NCT00199368 ↗	An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018	Completed	Kyowa Kirin, Inc.	Phase 3	2004-10-01	This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
NCT00199381 ↗	An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001	Terminated	Kyowa Kirin Pharmaceutical Development, Inc.	Phase 3	2005-10-01	This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.

Clinical Trial Conditions for ISTRADEFYLLINE

Condition Name

Condition Name for ISTRADEFYLLINE
Intervention	Trials
Parkinson's Disease	16
Idiopathic Parkinson's Disease	2
Parkinson Disease	2
Spinal Cord Injuries	1

Condition MeSH

Condition MeSH for ISTRADEFYLLINE
Intervention	Trials
Parkinson Disease	20
Cognitive Dysfunction	1
Sleep Wake Disorders	1
Wounds and Injuries	1

Clinical Trial Locations for ISTRADEFYLLINE

Trials by Country

Trials by Country for ISTRADEFYLLINE
Location	Trials
United States	54
Canada	6
Japan	5
Serbia	2
Germany	2

Trials by US State

Trials by US State for ISTRADEFYLLINE
Location	Trials
New Jersey	10
Massachusetts	3
Florida	3
Arizona	3
Virginia	2

Clinical Trial Progress for ISTRADEFYLLINE

Clinical Trial Phase

Clinical Trial Phase for ISTRADEFYLLINE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	10
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for ISTRADEFYLLINE
Clinical Trial Phase	Trials
Completed	20
Not yet recruiting	3
Terminated	1

Clinical Trial Sponsors for ISTRADEFYLLINE

Sponsor Name

Sponsor Name for ISTRADEFYLLINE
Sponsor	Trials
Kyowa Kirin, Inc.	11
Kyowa Kirin Pharmaceutical Development, Inc.	9
Kyowa Kirin Co., Ltd.	8

Sponsor Type

Sponsor Type for ISTRADEFYLLINE
Sponsor	Trials
Industry	37
Other	12